What question did this study set out to answer?

To evaluate the efficacy and mechanisms of relapse following CD19-specific CAR-T-cell therapy in patients with MLL-rearranged B-cell acute lymphoblastic leukemia.

February 24, 2016BloodOpen Access

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

View Full Paper

Ask AI

Bookmark

Authors

RGRebecca GardnerSt. Jude Children's Research Hospital DWDavid WuBeijing University of Chinese Medicine SCSindhu CherianUniversity of Washington

Discussion

Member takes

Implication

Clinical evaluation demonstrates lineage switch to acute myeloid leukemia after CD19 CAR-T-cell therapy in MLL-rearranged B-ALL, highlighting a novel mechanism of antigen-negative immune escape.

Key Points

To evaluate the efficacy and mechanisms of relapse following CD19-specific CAR-T-cell therapy in patients with MLL-rearranged B-cell acute lymphoblastic leukemia.
Administered lymphodepletion chemotherapy followed by CD19-targeted chimeric antigen receptor (CAR) T-cell infusions to 7 patients with relapsed or refractory MLL-rearranged B-ALL.
Assessed bone marrow response and phenotypic clonal evolution using flow cytometry.
All 7 patients achieved complete remission in the bone marrow by flow cytometry following CD19 CAR-T-cell infusion.
Within 1 month of infusion, 2 of 7 patients relapsed with acute myeloid leukemia that was clonally related to their original B-ALL, demonstrating CD19-negative lineage switching.

Cite This Study

Gardner et al. (2016) studied this question.

synapsesocial.com/papers/6a00a285b124fe581985f96c https://doi.org/10.1182/blood-2015-08-665547

View Full Paper

Ask AI

Bookmark

Implication

Clinical evaluation demonstrates lineage switch to acute myeloid leukemia after CD19 CAR-T-cell therapy in MLL-rearranged B-ALL, highlighting a novel mechanism of antigen-negative immune escape.

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider